Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Insilico Medicine (“Insilico”), a clinical-stage end-to-end artificial intelligence (AI)-driven drug discovery company, today announced that the company’s drug discovery team has nominated a preclinical candidate targeting KAT6A for ER+/HER2- breast cancer therapy utilizing its end-to-end Pharma.AI platform. The Company has…
Nano-sized membrane bubbles known as extracellular vesicles activate the immune system in mice and seem to render their tumors sensitive to a type of immunotherapy drug called a checkpoint inhibitor. This is according to a new study published in Cancer…
A team of researchers writing in the journal Angewandte Chemie has developed a bioorthogonal molecular system for the targeted introduction of nitrite ions into cells. Their system releases nitrite ions in cancer cells using a “click-to-release” strategy and these ions,…
Immune checkpoint inhibitors such as Keytruda and Opdivo work by unleashing the immune system’s T cells to attack tumor cells. Their introduction a decade ago marked a major advance in cancer therapy, but only 10% to 30% of treated patients…
In a recent study posted to the medRxiv* preprint server, a team of researchers explored the effect of immune checkpoint blockade (ICB)-induced expansion of age-associated B cells (ABCs) on coronavirus disease 2019 (COVID-19) vaccine-derived humoral immunity in patients with cancer…
A Ludwig Cancer Research study has identified a combination of three existing drugs that significantly extends survival in mouse models of the lethal brain cancer glioblastoma multiforme (GBM). Researchers led by Ludwig Lausanne’s Douglas Hanahan report in the current issue…